08:00 EDT Verve Therapeutics down 33% at $8.50 after pausing Heart-1 trial of VERVE-101
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics Announces Updates on its PCSK9 Program
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics price target lowered to $30 from $32 at Canaccord
- Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Verve Therapeutics reports Q4 EPS (69c), consensus (82c)
